Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

K-ras mutations in colorectal cancer: a practice changing discovery.

Clinical advances in hematology & oncology : H&O - 1 Jan 2009

Saif M Wasif, Shah Manasi

Abstract excerpt

Recent insights into the molecular pathogenesis of colorectal cancer have given rise to specific target-directed therapies, including monoclonal antibodies against epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF). These drugs have been approved as second and third line therapies for metastatic colorectal cancer (mCRC). Activating mutations of the K-Ras family of genes are the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Clinical Trials as Topic
Share to Colorectal Neoplasms
Share to Evidence-Based Medicine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to EGFR gene

Share to Mutation

Share to Proto-Oncogene Proteins

Share to Proto-Oncogene Proteins p21(ras)

Share to ras Proteins

Source

Identifiers

PMID: 19274041

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

K-ras mutations in colorectal cancer: a practice changing discovery.PMID 19274041Read ↗

Assessment of K-ras mutation: a step toward personalized medicine for patients with colorectal cancer.Semantic proximity Read ↗

KRAS mutation testing of colorectal cancer for anti-EGFR therapy: dogmas versus evidence.Semantic proximity Read ↗

BRAF Mutations in Colorectal Cancer: Clinical Relevance and Role in Targeted TherapySemantic proximity Read ↗

[Clinical relevance of the K-ras oncogene in colorectal cancer: experience in a Mexican population].Semantic proximity Read ↗

KRAS mutations in metastatic colorectal cancer: from a de facto ban on anti-EGFR treatment in the past to a potential biomarker for precision medicine.Semantic proximity Read ↗

An empirical review on the resistance mechanisms of epidermal growth factor receptor inhibitors and predictive molecular biomarkers in colorectal cancer.Semantic proximity Read ↗

Extended RAS Gene Mutation Testing in Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update 2015 Summary.Semantic proximity Read ↗

Japanese Society of Medical Oncology Clinical Guidelines: RAS (KRAS/NRAS) mutation testing in colorectal cancer patients.Semantic proximity Read ↗

Use of K-Ras as a predictive biomarker for selecting anti-EGF receptor/pathway treatment.Semantic proximity Read ↗

Targeting KRAS in Colorectal Cancer: A Bench to Bedside Review.Semantic proximity Read ↗

New Developments in Treating RAS-Mutated Metastatic Colorectal Cancer.Semantic proximity Read ↗

KRAS mutation testing in colorectal cancer as an example of the pathologist's role in personalized targeted therapy: a practical approach.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.